• slide1

    home

    Medical Diagnostics Anywhere.

  • slide2

    home2

    Medical Diagnostics Anywhere.

 

 

SAW Dx,
Medical Diagnostics Anywhere.

SAW Dx is an emerging point of care diagnostic (POC) device design and manufacturing venture focused on exploiting Acoustic-Flow technology based on the use of surface acoustic waves technology developed in the laboratory of Prof Jon Cooper, University of Glasgow.

 

The Acoustic-Flow technology utilises the interaction of Surface Acoustic Waves (SAW) with a patient sample to drive a diagnostic test. The interactions are controlled by
microstructures patterned on the surface of disposable chips, to shape sound in particular ways in a frequency dependant manner. Functions possible include fluid movement, mixing, particle patterning, enrichment, opening cells to release DNA and temperature cycling of a sample. Acoustic-Flow technology means that samples can be processed on-chip (no preprocessing required) and complex micro-fluidics are avoided.

 

The SAW Dx business model is based on providing product and technology solutions to life sciences and diagnostics companies seeking to enhance their diagnostic product offerings through innovative point of care use.

Make an Enquiry

 

Name:

Phone:

Email:

Enquiry:

 

 

 

 

 

Partnering

SAW Dx is a technology development company providing solutions to the life sciences and diagnostics industry through the following routes:

  1. Exploiting proprietary acoustic sample manipulation technologies to build components/devices/systems for laboratory, point of care and home/remote testing applications
  2. Co-development contracts with life science/diagnostic companies looking to enter new markets or to enhance existing product offering.

SAW Dx provides services in the design, build and testing of products incorporating its Acoustic-Flow technology.

Make an Enquiry

 

Name:

Phone:

Email:

Enquiry:

 

 

Team

Prof Jon Cooper – Director & Academic Founder; holds the Wolfson Chair in Biomedical Engineering; Fellow of the Royal Society of Edinburgh; Fellow of Royal Academy of Engineering; Royal Society Wolfson Research Merit Award. Spin-out companies include – Mode-Dx and Clyde Biosciences.

 

Dr Kate Rowley, Director, IP Group plc – represents the investment company IP Group plc on the Board. She has over 20 years’ experience in the life sciences sector, working in the NHS, large pharma, public and private sectors.

 

Prof Steve Beaumont, Director, GU Holdings Limited; VP Research & Enterprise, University of Glasgow

Steve Beaumont is a Chartered Engineer (CEng); Fellow of the Royal Society of Edinburgh (FRSE); Fellow of the Royal Academy of Engineering (FREng). He has significant experience in developing spin-out companies. Steve represents the University’s interests on the Board through its subsidiary GU Holdings Limited

 

Dr. Julien Reboud – founder is a Lord Kelvin and Adam Smith University Research Fellow at Glasgow University (UK). He is a co-inventor of the acoustic technology, for which he recently was awarded The Royal Academy of Engineering ERA Foundation Entrepreneurs prize (2013).

 

Dr. Rab Wilson – founder Is a post-doctoral research assistant in Glasgow. He studied Mathematics with Theoretical Physics at the University of Aberdeen and after an MSc. in Advanced Materials at Cranfield University, obtained an industrially-funded PhD investigating ferroelectric thin films. He is a co-inventor of the SAW Dx technology.

Make an Enquiry

 

Name:

Phone:

Email:

Enquiry:

 

 

Technology

The technology utilises the interaction of Surface Acoustic Waves (SAW) with a patient sample to drive a diagnostic test. The interactions are controlled by microstructures patterned on the surface of disposable chips, to shape sound in particular ways in a frequency dependant manner. Demonstrated functions include fluid movement, mixing, particle patterning, enrichment, opening cells to release DNA and temperature cycling of a sample. Acoustic-Flow technology means that samples can be processed on-chip (no pre-processing required) and complex micro-fluidics are avoided.

Benefits :

  • Rapid results (<30 minutes for nucleic acid tests – NATs, <10 min for immunoassays)
  • No pre-processing of samples
  • Clinic, Community or Field use – can be battery powered (hundreds of tests on one charge of a mobile phone)
  • Various formats – lab-based to hand held; Many different tests accommodated

 

diagram

 

Make an Enquiry

 

Name:

Phone:

Email:

Enquiry:

 

 

Development Programs

NHS Scotland

#1: Sexually Transmitted Infections (STI’s) with the NHS Greater Glasgow & Clyde

A point of care ‘board and wires’ prototype for use in rapid diagnosis of Sexually Transmitted Infections (STI’s) specifically syphilis and HSV (types 1&2) from the same patient sample has been constructed and tested, with funding from an ERC advanced fellowship. The assays are proprietary to the NHS and SAW Dx is providing the technology platform. The next step is to perform a proof-of-concept study (first-in-man) to demonstrate competitive advantages.

 

Current lab tests require the patient to return to the clinic days later, leading just over one third of people not returning in the UK, who have to be followed up. The SAW Dx platform enables to break the cycle of infection by allowing treatment before people leave the clinic and do not return.

 

epigem

#2: Tuberculosis (funded by the TSB) in collaboration with EPIGEM Ltd, and clinical partners at Edinburgh, Southampton, and University College London.

Development of a point of care demonstrator reader and disposable cartridge for use with existing diagnostic assays for tuberculosis (including latent TB). Latent TB (when the patient is infected but without symptoms) is particularly hard to detect and with 10% of these patients going on to develop full TB then new detection methods are required.

 

Bill and Melinda Gates Foundation

#3: Developing World Diagnostics

Infectious diseases continue to decimate human (and animal) health in many parts of the world. Malaria afflicts nearly 300 million people each year, killing over 0.6 million, mainly children. Other diseases such as the trypanosomiases (African and American) and leishmaniases affect many millions the world over and helminth infections run into the billions. In many instances methods exist to manage diseases caused by these infections. However, in order to implement suitable control strategies, it is necessary to first make accurate and sensitive diagnosis of the disease.

 

The SAW Dx team, in partnership with parasitologists at the University of Glasgow), has built a low power (battery-operated) plaform, to enrich parasites and perform cell lysis and molecular detection, on low-cost disposable chips.

 

 

 

Make an Enquiry….

Name:

Phone:

Email:

Enquiry:

 

Contact Details

 

SAW DX Ltd

11 The Square

University of Glasgow

University Avenue

Glasgow, G12 8QQ

United Kingdom

 

Professor Jon Cooper

E-Mail: info@sawdx.com

 

 

 

 

 

Recruitment

to contact us, please use the form on the right.

There is currently no opening available

Make an Enquiry

 

Name:

Phone:

Email:

Enquiry: